The association between pre-treatment serum 25-hydroxyvitamin D and survival in stage IV prostate cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5036-5036
Author(s):  
Pankaj G. Vashi ◽  
Digant Gupta ◽  
Kristen Trukova ◽  
Gwendolyn M Lambert ◽  
Carolyn Lammersfeld
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Patient Survival ◽  
Stage Iv ◽  
Vitamin D Insufficiency ◽  
Newly Diagnosed ◽  
Baseline Serum ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

5036 Background: Emerging evidence in the literature suggests a positive association between serum 25-hydroxyvitamin D [25(OH)D], a standard indicator of vitamin D status, and survival in certain types of cancer. We investigated this relationship in newly diagnosed stage IV prostate cancer patients. Methods: A case series of 54 newly diagnosed stage IV prostate cancer patients underwent a baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between Jan 2008 and Dec 2010. We defined vitamin D insufficiency as serum 25(OH)D levels of <=32 ng/ml. Patient survival was defined as the time between date of first patient visit and date of death from any cause/date of last contact. Cox regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for age, prostate specific antigen (PSA) and functional status. Results: Mean age at diagnosis was 59.6 years. During a median follow-up of 23.6 months, 16 deaths occurred. The mean serum 25(OH)D was 30.1 ng/ml, among whom 38 (70.4%) were insufficient in vitamin D (<=32 ng/ml). Mean overall survival was 49.4 months (95% CI: 38.1-60.7). Mean survival was 32.6 months and 62.4 months for patients in <=32 ng/ml and >32 ng/ml groups respectively (p = 0.02). On univariate analysis, patients with levels >32 ng/ml had a significantly lower risk of mortality compared to those with levels <=32 ng/ml (HR=0.19; 95% CI: 0.04-0.87; p=0.03). On multivariate analysis controlling for age, performance status and PSA, patients with levels >32 ng/ml demonstrated significantly lower mortality (HR=0.13; 95% CI: 0.02-1.0; p=0.05) compared to those with levels <=32 ng/ml. Conclusions: Higher circulating levels of serum 25(OH)D were positively associated with survival in patients with metastatic prostate cancer. While these results need to be confirmed in prospective clinical trials, our study adds to the growing body of literature on the prognostic role of serum vitamin D in cancer. Given the high prevalence of vitamin D insufficiency in prostate cancer and the fact that this insufficiency is easily correctable by supplementation, we recommend early vitamin D assessment and intervention for a potential impact on patient survival.

Vitamin D status is related to severity at onset of diabetes and worse glycemic control

2020 ◽  
Vol 33 (10) ◽  
pp. 1265-1271
Author(s):  
Raquel Segovia-Ortí ◽  
Antonia Barceló Bennassar ◽  
Diego de Sotto-Esteban ◽  
Pilar Sanchís Cortés
Keyword(s):  
Vitamin D ◽  
Glycemic Control ◽  
Glycosylated Hemoglobin ◽  
Winter Season ◽  
Hypovitaminosis D ◽  
Vitamin D Insufficiency ◽  
Baseline Serum ◽  
Hydroxyvitamin D ◽  
Bivariate Correlation ◽  
25 Hydroxyvitamin D

AbstractObjectivesOur aim is to evaluate whether 25-hydroxyvitamin D at onset of type 1 diabetes mellitus (T1DM) would influence analytical variables of worse prognosis of the disease at the beginning and after one year of development.MethodsA retrospective study of pediatric patients (0–14 years) diagnosed with T1DM with initial measurements of 25-hydroxyvitamin D was performed at Son Espases Hospital, between March 2012 and April 2019 (n=67).ResultsVitamin D insufficiency was related to age, glycosylated hemoglobin, and creatinine. An improvement in glycosylated hemoglobin was found in subjects whose baseline serum 25(OH)D was >30 ng/mL. Bivariate correlation analysis adjusted by age showed a significantly positive correlation of vitamin D with pH (r=0.279), bicarbonate (r=0.338), and free levothyroxine (r=0.293). Independent variables associated with vitamin D insufficiency were age (odds ratio [OR]=1.2) and winter season (OR=10.52).ConclusionHypovitaminosis D is related to biochemical variables showing greater severity and higher glycosylated hemoglobin at diagnosis: higher creatinine, lower free levothyroxine, pH, and bicarbonate. Unsupplemented patients with baseline deficiency showed persistently worse glycemic control vs. those with baseline repletion.

scholarly journals Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis

2018 ◽  
Vol 7 (12) ◽  
pp. R294-R303 ◽  
Author(s):  
Zhen-yu Song ◽  
Qiuming Yao ◽  
Zhiyuan Zhuo ◽  
Zhe Ma ◽  
Gang Chen
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Dose Response ◽  
Protective Factor ◽  
Meta Analysis ◽  
Random Effect Model ◽  
Hydroxyvitamin D ◽  
Risk Of Death ◽  
25 Hydroxyvitamin D

Previous studies investigating the association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer yielded controversial results. We conducted a dose–response meta-analysis to elucidate the relationship. PubMed and EMBASE were searched for eligible studies up to July 15, 2018. We performed a dose–response meta-analysis using random-effect model to calculate the summary hazard ratio (HR) and 95% CI of mortality in patients with prostate cancer. Seven eligible cohort studies with 7808 participants were included. The results indicated that higher vitamin D level could reduce the risk of death among prostate cancer patients. The summary HR of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D level was 0.91, with 95% CI 0.87–0.97, P = 0.002. The HR for all-cause mortality with the increase of 20 nmol/L vitamin D was 0.91 (95% CI: 0.84–0.98, P = 0.01). Sensitivity analysis suggested the pooled HRs were stable and not obviously changed by any single study. No evidence of publications bias was observed. This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.

scholarly journals The Association between Pre-Treatment Serum 25-Hydroxyvitamin D and Survival in Newly Diagnosed Stage IV Prostate Cancer

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0119690 ◽  
Author(s):  
Digant Gupta ◽  
Kristen Trukova ◽  
Brenten Popiel ◽  
Carolyn Lammersfeld ◽  
Pankaj G. Vashi
Keyword(s):  
Prostate Cancer ◽  
Stage Iv ◽  
Newly Diagnosed ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Pre Treatment

scholarly journals Association of serum 25-hydroxyvitamin D with prevalence, incidence, and clearance of vaginal HPV infection in young women

2020 ◽  
Author(s):  
Mariam El-Zein ◽  
Farzin Khosrow-Khavar ◽  
Ann N Burchell ◽  
Pierre-Paul Tellier ◽  
Shaun Eintracht ◽  
...  
Keyword(s):  
Vitamin D ◽  
Proportional Hazards ◽  
Hpv Infection ◽  
Cox Proportional Hazards ◽  
Baseline Serum ◽  
Hpv Dna ◽  
Hydroxyvitamin D ◽  
Hpv Prevalence ◽  
Vitamin D Levels ◽  
25 Hydroxyvitamin D

Abstract Background We assessed the association between serum 25-hydroxyvitamin D levels and genital human papillomavirus (HPV) prevalence, incidence, and clearance among female participants of the HITCH cohort study. Methods We genotyped HPV DNA in vaginal samples and quantified baseline serum 25-hydroxyvitamin D levels using Roche’s Linear Array and Total vitamin D assay, respectively. We used logistic and Cox proportional hazards models to respectively estimate adjusted odds ratios (OR) and hazards ratios (HR) with 95% confidence intervals (CI). Results There was no association between vitamin D levels (every 10ng/mL increase) at baseline and HPV prevalence (OR=0.88, CI:0.73-1.03) or incidence (HR=0.88, CI:0.73-1.06), but we observed a modest negative association with HPV clearance (HR=0.76, CI:0.60-0.96). Vitamin D levels &lt;30ng/mL, compared to ≥30ng/mL, were not associated with HPV prevalence (OR=0.98, CI:0.57-1.69) or incidence (HR=0.87, CI:0.50-1.43), but were associated with a marginally significant increased clearance (OR=2.14, CI:0.99-4.64). We observed consistent results with restricted cubic spline modelling of vitamin D levels and clinically defined categories. HPV type-specific analyses accounting for multiple HPV infections per participant showed no association between vitamin D levels and all study outcomes. Conclusion This study provided no evidence of an association between low vitamin D levels and increased HPV prevalence, acquisition, or clearance.

scholarly journals Circulating 25‐hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer

2018 ◽  
Vol 144 (10) ◽  
pp. 2401-2407 ◽  
Author(s):  
Chen Yuan ◽  
Irene M. Shui ◽  
Kathryn M. Wilson ◽  
Meir J. Stampfer ◽  
Lorelei A. Mucci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Binding Protein ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Lethal Prostate Cancer

scholarly journals Effect of Vitamin D Supplementation on Survival of Digestive Tract Cancer Patients with Low Bioavailable 25-Hydroxyvitamin D Levels: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 347 ◽  
Author(s):  
Mitsuyoshi Urashima ◽  
Mai Okuyama ◽  
Taisuke Akutsu ◽  
Hironori Ohdaira ◽  
Mutsumi Kaji ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cancer Patients ◽  
Digestive Tract ◽  
Vitamin D Supplementation ◽  
Digestive Tract Cancer ◽  
Post Hoc Analysis ◽  
Hydroxyvitamin D ◽  
Tract Cancer ◽  
25 Hydroxyvitamin D ◽  
Post Hoc

Vitamin D has been shown to suppress the growth of cancer cells. Cancer cells are believed to take up bioavailable 25-hydroxyvitamin D (25[OH]D) (i.e., not bound to vitamin-D-binding protein (DBP)) more efficiently than DBP-bound 25(OH)D. Our aim was to use this bioavailable 25(OH)D, rather than total 25(OH)D, as a biomarker of vitamin D deficiency to investigate whether vitamin D supplementation improves the relapse-free survival (RFS) of patients with digestive tract cancer from the esophagus to the rectum by conducting a post hoc analysis of the AMATERASU trial (UMIN000001977). The bioavailable 25(OH)D levels were calculated via an equation using data of serum total 25(OH)D, albumin, and DBP levels, and DBP genotypes (rs7041 and rs4588). We estimated bioavailable 25(OH) levels in 355 patients. In a subgroup of patients with low bioavailable 25(OH)D levels (<median) (n = 177), 5 year RFS was 77% in the vitamin D group vs. 58% in the placebo group (hazard ratio, 0.54; 95% confidence interval, 0.31–0.95; p = 0.03), whereas no significant difference was seen in a subgroup of patients with high bioavailable 25(OH)D levels (p for interaction = 0.046). We hypothesize that vitamin D supplementation may be effective in improving RFS among digestive tract cancer patients with low bioavailable 25(OH)D levels.

scholarly journals Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer

2012 ◽  
Vol 132 (12) ◽  
pp. 2940-2947 ◽  
Author(s):  
Stephanie J. Weinstein ◽  
Alison M. Mondul ◽  
William Kopp ◽  
Helen Rager ◽  
Jarmo Virtamo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Binding Protein ◽  
Vitamin D Binding Protein ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

scholarly journals Vitamin D Status in Japanese Adults: Relationship of Serum 25-Hydroxyvitamin D with Simultaneously Measured Dietary Vitamin D Intake and Ultraviolet Ray Exposure

Nutrients ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 743 ◽  
Author(s):  
Keiko Asakura ◽  
Norihito Etoh ◽  
Haruhiko Imamura ◽  
Takehiro Michikawa ◽  
Takahiro Nakamura ◽  
...  
Keyword(s):  
Vitamin D ◽  
Exposure Time ◽  
Serum Vitamin ◽  
Vitamin D Insufficiency ◽  
Uv Exposure ◽  
Dietary Vitamin ◽  
Hydroxyvitamin D ◽  
Vitamin D Intake ◽  
25 Hydroxyvitamin D ◽  
Ultraviolet Ray

Vitamin D insufficiency/deficiency is prevalent worldwide. We investigated the effect of vitamin D intake and ultraviolet ray (UV) exposure on serum vitamin D concentration in Japan. A total of 107 healthy adult participants were recruited from Hokkaido (43° N) and Kumamoto (33° N) prefectures. All participants undertook surveys in both summer and winter. Serum 25-hydroxyvitamin D (25(OH)D3) was examined, and vitamin D intake was assessed with a diet history questionnaire. UV exposure was measured with a wearable UV dosimeter. Regression analysis was performed to investigate the relationship between these factors, with covariates such as sun avoidance behavior. The prevalence of vitamin D insufficiency (serum 25(OH)D3; 12 ng/mL (30 nmol/L) ≤ and <20 ng/mL (50 nmol/L))/deficiency (<12 ng/mL) was 47.7% in summer and 82.2% in winter. UV exposure time was short in Kumamoto (the urban area), at 11.6 min in summer and 14.9 min in winter. In Hokkaido (the rural area), UV exposure time was 58.3 min in summer and 22.5 min in winter. Vitamin D intake was significantly associated with serum 25(OH)D3, and a 1 μg/1000kcal increase in intake was necessary to increase 25(OH)D3 by 0.88 ng/mL in summer and by 1.7 ng/mL in winter. UV exposure time was significantly associated with serum 25(OH)D3 in summer, and a 10 min increase in UV exposure time was necessary to increase 25(OH)D3 by 0.47 ng/mL. Although consideration of personal occupation and lifestyle is necessary, most Japanese may need to increase both vitamin D intake and UV exposure.

Sign in / Sign up

Export Citation Format

Share Document